Cullinan Therapeutics and Taiho have a significant market opportunity with zipalertinib after successful results in the Phase I/II REZILIENT1 trial among previously treated non-small cell lung cancer (NSCLC) patients whose disease harbors epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Cullinan/Taiho’s Zipalertinib Stands To Benefit From A Clear Market
The two companies announced positive topline results for the drug in pretreated EGFR exon 20 insertion mutation NSCLC, a market that Takeda vacated in 2023.
More from Anticancer
More from Scrip
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.